These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 36238297)

  • 1. Recent advances in CAR-T cells therapy for colorectal cancer.
    Qin X; Wu F; Chen C; Li Q
    Front Immunol; 2022; 13():904137. PubMed ID: 36238297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Advances of CAR-T cell therapy in treating colorectal cancer].
    Chao Z; Liu W; Liu Y
    Sheng Wu Gong Cheng Xue Bao; 2024 May; 40(5):1365-1379. PubMed ID: 38783803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
    Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
    Front Immunol; 2018; 9():1717. PubMed ID: 30108584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Updated Clinical Perspectives and Challenges of Chimeric Antigen Receptor-T Cell Therapy in Colorectal Cancer and Invasive Breast Cancer.
    Cao Y; Efetov SK; He M; Fu Y; Beeraka NM; Zhang J; Zhang X; Bannimath N; Chen K
    Arch Immunol Ther Exp (Warsz); 2023 Aug; 71(1):19. PubMed ID: 37566162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges of chimeric antigen receptor-T/natural killer cell therapy in the treatment of solid tumors: focus on colorectal cancer and evaluation of combination therapies.
    Wang H; Pan W
    Mol Cell Biochem; 2023 May; 478(5):967-980. PubMed ID: 36190614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adoptive cell therapy for solid tumors beyond CAR-T: Current challenges and emerging therapeutic advances.
    Zhang T; Tai Z; Miao F; Zhang X; Li J; Zhu Q; Wei H; Chen Z
    J Control Release; 2024 Apr; 368():372-396. PubMed ID: 38408567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge.
    Guedan S; Alemany R
    Front Immunol; 2018; 9():2460. PubMed ID: 30405639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancing CAR T-cell therapies against solid tumors: Mechanisms and reversion of resistance.
    Qin Y; Xu G
    Front Immunol; 2022; 13():1053120. PubMed ID: 36569859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells.
    Aparicio C; Belver M; Enríquez L; Espeso F; Núñez L; Sánchez A; de la Fuente MÁ; González-Vallinas M
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities.
    Chen L; Chen F; Niu H; Li J; Pu Y; Yang C; Wang Y; Huang R; Li K; Lei Y; Huang Y
    Front Immunol; 2022; 13():871661. PubMed ID: 35911706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
    Zhang E; Gu J; Xu H
    Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Present Status and Advances in Chimeric Antigen Receptor T Cell Therapy for Glioblastoma.
    Zhou S; Sun H; Choi SI; Yin J
    Front Biosci (Landmark Ed); 2023 Sep; 28(9):206. PubMed ID: 37796692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CAR T-cells for colorectal cancer immunotherapy: Ready to go?
    Ghazi B; El Ghanmi A; Kandoussi S; Ghouzlani A; Badou A
    Front Immunol; 2022; 13():978195. PubMed ID: 36458008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric Antigen Receptor T-Cell Therapy: Current Perspective on T Cell-Intrinsic, T Cell-Extrinsic, and Therapeutic Limitations.
    Brookens SK; Posey AD
    Cancer J; 2023 Jan-Feb 01; 29(1):28-33. PubMed ID: 36693155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies.
    Keshavarz A; Salehi A; Khosravi S; Shariati Y; Nasrabadi N; Kahrizi MS; Maghsoodi S; Mardi A; Azizi R; Jamali S; Fotovat F
    Stem Cell Res Ther; 2022 Sep; 13(1):482. PubMed ID: 36153626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
    Martinez M; Moon EK
    Front Immunol; 2019; 10():128. PubMed ID: 30804938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical Evaluation of Chimeric Antigen Receptor-Modified T Cells Specific to Epithelial Cell Adhesion Molecule for Treating Colorectal Cancer.
    Zhang BL; Li D; Gong YL; Huang Y; Qin DY; Jiang L; Liang X; Yang X; Gou HF; Wang YS; Wei YQ; Wang W
    Hum Gene Ther; 2019 Apr; 30(4):402-412. PubMed ID: 30693795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
    Kosti P; Maher J; Arnold JN
    Front Immunol; 2018; 9():1104. PubMed ID: 29872437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiotherapy to Enhance Chimeric Antigen Receptor T-Cell Therapeutic Efficacy in Solid Tumors: A Narrative Review.
    Hauth F; Ho AY; Ferrone S; Duda DG
    JAMA Oncol; 2021 Jul; 7(7):1051-1059. PubMed ID: 33885725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases.
    Magee MS; Abraham TS; Baybutt TR; Flickinger JC; Ridge NA; Marszalowicz GP; Prajapati P; Hersperger AR; Waldman SA; Snook AE
    Cancer Immunol Res; 2018 May; 6(5):509-516. PubMed ID: 29615399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.